Charles Schwab Trust Co Trims Position in Eli Lilly and Company (NYSE:LLY)

Charles Schwab Trust Co lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 21.8% during the third quarter, HoldingsChannel reports. The firm owned 226 shares of the company’s stock after selling 63 shares during the quarter. Charles Schwab Trust Co’s holdings in Eli Lilly and Company were worth $200,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Lynx Investment Advisory acquired a new stake in shares of Eli Lilly and Company in the second quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new position in shares of Eli Lilly and Company during the second quarter worth about $36,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the first quarter worth about $40,000. Morton Brown Family Wealth LLC boosted its position in shares of Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Richardson Financial Services Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Guggenheim boosted their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,025.00 price target on shares of Eli Lilly and Company in a report on Thursday, October 3rd. Jefferies Financial Group boosted their price objective on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Finally, Barclays boosted their price target on Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 10th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $979.29.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $15.34 during midday trading on Friday, reaching $926.03. 1,231,814 shares of the company traded hands, compared to its average volume of 3,004,167. The firm has a market capitalization of $880.13 billion, a price-to-earnings ratio of 113.34, a price-to-earnings-growth ratio of 2.79 and a beta of 0.42. The company has a fifty day moving average price of $908.28 and a 200 day moving average price of $851.21. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The company had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. On average, analysts expect that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.